Aptinyx News Releases https://ir.aptinyx.com/ Aptinyx News Releases en Aptinyx to Present at the 2019 BMO Prescription for Success Healthcare Conference https://ir.aptinyx.com/news-releases/news-release-details/aptinyx-present-2019-bmo-prescription-success-healthcare EVANSTON, Ill., June 18, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Ashish Khanna , chief financial officer and chief business Tue, 18 Jun 2019 08:27:00 -0400 Aptinyx News Releases 7281 Aptinyx Reports Positive Top-line Data from Phase 2 Study of NYX-2925 in Patients with Fibromyalgia, Demonstrating Significant Effects on Both Biomarkers and Patient-Reported Pain https://ir.aptinyx.com/news-releases/news-release-details/aptinyx-reports-positive-top-line-data-phase-2-study-nyx-2925 NYX-2925 demonstrated statistically significant effects on a range of neuroimaging biomarkers and patient-reported outcomes, including pain scores Neuroimaging biomarkers correlated with patient-reported pain improvements NYX-2925 was well tolerated with no serious adverse events reported Mon, 10 Jun 2019 07:23:00 -0400 Aptinyx News Releases 7261 Aptinyx Reports First Quarter 2019 Financial Results and Provides Corporate Update https://ir.aptinyx.com/news-releases/news-release-details/aptinyx-reports-first-quarter-2019-financial-results-and Four Phase 2 studies expected to be ongoing by year end; multiple data read-outs anticipated in 2019 and 2020 Management to host conference call today at 8:00 a.m. ET EVANSTON, Ill. , May 14, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing Tue, 14 May 2019 06:27:00 -0400 Aptinyx News Releases 7186 Aptinyx Appoints Henry Gosebruch to Its Board of Directors https://ir.aptinyx.com/news-releases/news-release-details/aptinyx-appoints-henry-gosebruch-its-board-directors Chief Strategy Officer at AbbVie and former co-head of J.P. Morgan’s North American M&A Group becomes eighth member of Aptinyx board EVANSTON, Ill. , May 07, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the Tue, 07 May 2019 07:23:00 -0400 Aptinyx News Releases 7166 Aptinyx to Report First Quarter 2019 Financial Results on Tuesday, May 14, 2019 https://ir.aptinyx.com/news-releases/news-release-details/aptinyx-report-first-quarter-2019-financial-results-tuesday-may EVANSTON, Ill., May 06, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Mon, 06 May 2019 07:27:00 -0400 Aptinyx News Releases 7156 Aptinyx Reports Positive Data from Phase 1 Study of Novel NMDA Receptor Modulator, NYX-458, in Healthy Volunteers https://ir.aptinyx.com/news-releases/news-release-details/aptinyx-reports-positive-data-phase-1-study-novel-nmda-receptor Favorable overall safety, tolerability, and pharmacokinetic profile — no serious adverse events reported across wide dose range Achieved ample CNS exposure consistent with exposure observed at preclinically efficacious doses Expect to initiate Phase 2a study in patients with cognitive impairment Tue, 30 Apr 2019 07:27:00 -0400 Aptinyx News Releases 7136 Robust Analgesic Activity of Aptinyx’s NYX-2925 in Advanced DPN Patients Revealed Through Further Analysis of Data from Phase 2 Study https://ir.aptinyx.com/news-releases/news-release-details/robust-analgesic-activity-aptinyxs-nyx-2925-advanced-dpn M echanism of NYX-2925 is highly relevant in advanced DPN patients with longer duration of chronic pain The above graph depicts a post hoc analysis showing the reduction in average daily pain from baseline in patients who have had DPN for four years or longer. Thu, 18 Apr 2019 07:27:00 -0400 Aptinyx News Releases 7131 Aptinyx to Present at 18th Annual Needham Healthcare Conference https://ir.aptinyx.com/news-releases/news-release-details/aptinyx-present-18th-annual-needham-healthcare-conference EVANSTON, Ill., April 04, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel , Ph.D., president and CEO, will present at the Thu, 04 Apr 2019 08:00:00 -0400 Aptinyx News Releases 7116 Data in Parkinson’s Disease Model in Non-human Primates Demonstrate Reversal of Cognitive Deficits with Novel NMDA Receptor Modulator, NYX-458 https://ir.aptinyx.com/news-releases/news-release-details/data-parkinsons-disease-model-non-human-primates-demonstrate EVANSTON, Ill. , April 03, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced positive preclinical data on its novel NMDA receptor modulator, Wed, 03 Apr 2019 07:27:00 -0400 Aptinyx News Releases 7111 Aptinyx to Present Detailed Results from Phase 2 Painful DPN Study of NYX-2925 at American Pain Society Scientific Meeting https://ir.aptinyx.com/news-releases/news-release-details/aptinyx-present-detailed-results-phase-2-painful-dpn-study-nyx EVANSTON, Ill., March 28, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced an upcoming poster presentation highlighting the detailed results Thu, 28 Mar 2019 07:07:00 -0400 Aptinyx News Releases 7041